News

News 20.04.2020 Zurich-Schlieren, Switzerland, April 20, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, has identified multiple potent monospecific DARPin® proteins which neutralize samples of the SARS-CoV-2 virus. The company has engineered these proteins into trispecific antiviral...

News 02.04.2020 Schlieren and St. Gallen, Switzerland, April 2, 2020. The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer diagnosis, is made available by the Center for Laboratory Medicine St. Gallen (Zentrum für Labormedizin St. Gallen, ZLM). ”Proclarix is...

News 26.03.2020 Schlieren (Zurich), Switzerland, March 26, 2020 – Kuros Biosciences successfully delivered on its targets in 2019, increasing sales of MagnetOs fivefold and confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised gross proceeds of CHF 12.5 million from a capital...

News 18.03.2020 Schlieren (Zurich), Switzerland, March 18, 2020 – Kuros Biosciences (SIX: KURN) today announced that its subsidiary, Kuros Biosurgery AG, has been granted the US patent, US 10’589’001, entitled ‘Pharmaceutical formulation for use in spinal fusion’. This patent covers the use of parathyroid hormone (PTH) containing matrices for spinal fusion. The granting...

News 28.02.2020 Zurich, Switzerland – February 27, 2020 – Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy). NI006 is a human antibody directed against transthyretin amyloid (TTR amyloid) consisting of misfolded...